Also categorized in Clinical Research:
A Phase I Study of Panitumumab in Children with Solid Tumors
x hide permanently

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

ncbi.nlm.nih.gov

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

Oncotarget. 2018 Jan 05;9(2):2304-2319

Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

Mentions: MYCN